Clinical Trial Finder

Inclusion Criteria:

• - Male and female patients aged ≥70 yrs identified through the neurooncology MDT.

• - A histological diagnosis of HGG, either from biopsy or resection.

• - A life expectancy of > 2 months.

• - An ECOG performance status of 0/1.

• - Absolute neutrophil count ≥ 1.5 x 109.

• - Platelet count ≥ 100 x 109.

• - Bilirubin ≤ 1.5 mg/dL (or ≤ 25.6 µmol/L) - Creatinine ≤ 2 times upper limit of normal (ULN) - ALT and AST ≤ 4 times ULN.

• - Mini Mental Status Exam score ≥ 17 (Appendix 10) - Written informed consent.

• - Ready to start radiotherapy within 4 weeks of surgery.

Exclusion Criteria:

• - Concurrent psoriasis unless the disease is well controlled and patient is under the care of a specialist for the disorder who agrees to monitor for exacerbations.

• - Prior macular degeneration or diabetic retinopathy.

• - Concurrent serious infection or medical illness that would preclude study therapy.

• - Another malignancy within the past 5 years except for curatively treated carcinoma in situ or basal cell carcinoma of the skin.

• - Porphyria.

• - Glucose- 6 phosphate dehydrogenase (G6PD) deficiency.

• - Alcoholic liver disease.

• - Any other concurrent severe/uncontrolled medical conditions.

• - Currently taking amiodarone.

• - Prior radiotherapy, chemotherapy, immunotherapy, biologic agents (e.g., immunotoxins, immunoconjugates, antisense agents, peptide receptor antagonists, interferons, interleukins, tumour-infiltrating lymphocytes, lymphokine-activated killer cell therapy, or gene therapy), or hormonal therapy for brain tumour.

• - Prior polifeprosan 20 with carmustine implant (Gliadel wafer) or GliaSite® brachytherapy.

• - Concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (e.g., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine) - Other concurrent chemotherapeutic or investigational agents for this cancer (Concurrent glucocorticoids will be allowed.

• - Documented side effects to chloroquine or related agents.

• - Unable to give informed consent.

- Patients with a history of a psychological illness or condition that in the opinion of the investigator may adversely affect compliance with study medication

Arms

Experimental: Arm B

Patients randomised to Arm B will receive Short Course Radiotherapy plus Hydroxychloroquine 200mg bd from 14 days post surgery until clinical or radiological progression.

Active Comparator: Arm A: SCRT alone

Patients randomised to Arm A will receive standard treatment of Short Course Radiotherapy

Interventions

Drug: - Hydroxychloroquine

200mg bd from 14 days post surgery until clinical or radiological progression

Radiation: - Radiotherapy

Short Course radiotherapy